<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F2004696-9375-4C0A-AD85-77C5C8426BD2"><gtr:id>F2004696-9375-4C0A-AD85-77C5C8426BD2</gtr:id><gtr:firstName>Klaus</gtr:firstName><gtr:surname>Okkenhaug</gtr:surname><gtr:orcidId>0000-0002-9432-4051</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F0000H329"><gtr:id>32524AFD-A66D-4B60-AB6C-750869312443</gtr:id><gtr:title>PIK signalling in Immunity and Infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/0000H329</gtr:grantReference><gtr:abstractText>The developed world has observed a dramatic reduction in mortality due to infections over the last century. At the same time, certain cancers, allergy and autoimmune disease are on the rise. Moreover, re-emerging and novel pathogens such as HIV, flu and various bacterial infections target vulnerable populations everywhere. As a consequence, a substantial effort is still required to find strategies to target the immune system in ways that reduce autoimmune, allergic and inflammatory diseases while retaining optimal protection from pathogens. In this programme, we will explore how experimental and eventually therapeutic modulation of the PI3K signalling module affects different components of the immune system. We will apply this knowledge to suggest how manipulation of PI3K signalling can be used to promote immunological health and improved lifespan.</gtr:abstractText><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>74170</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Discussed animal research on Cambridge TV</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A1E5AC31-6E50-4D02-B583-6295E212D144</gtr:id><gtr:impact>I was interviewed for a programme aired on Cambridge TV about the use of animals in research.</gtr:impact><gtr:outcomeId>58ca5c8da011b5.88959634</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cambridge-tv.co.uk/impact-animal-research/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Summer Exhibition, 2015: Immune Army</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>19B47A95-2BDC-4F7B-9540-EC58A8FAEE73</gtr:id><gtr:impact>We presented our exhibition: &amp;quot;Immune Army: weapons of microscopic destruction&amp;quot;; at the Royal Society Summer exhibition 2015. Many members of my lab participated in the design of the exhibition materials, the accompanying video (https://youtu.be/oMj8UxMPYJU) and at the exhibition itself. I spent two full days at the exhibition. Work on Activated PI3K Delta Syndrome (APDS) and Cancer immunotherapy from my lab featured prominently in this exhibition.</gtr:impact><gtr:outcomeId>56a8b93b976090.93851263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://sse.royalsociety.org/2015/immune-army/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC MICA programme grant</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M012328/2</gtr:fundingRef><gtr:id>CD37CCF5-CF7A-4E7D-8404-F59529DD89F9</gtr:id><gtr:outcomeId>56c2132eea1520.40181919</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have generated new a new mouse model mimicking a newly described primary immune deficiency which will help us understand why APDS patients are susceptible to airway infections.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>1D6A83CF-C3F9-4612-9C7F-0FB695D7741D</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544fb627ed4a81.57524582</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Gilead Oncology Faculty</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C52FDF07-0A71-498A-8B1F-7947EC48E18B</gtr:id><gtr:impact>Following the EMA approval of Zydelig&amp;reg; (idelalisib) in September 2014, and the presentation of new data on idelalisib at ASH 2014, Gilead medical affairs launched a new idelalisib speaker programme, known as &amp;quot;Gilead Oncology Faculty&amp;quot;. This medically led, non-promotional activity aims to provide engaged experts the opportunity to be trained on idelalisib data of high quality and scientific content (on label; new indications and new oncology drugs within the Gilead portfolio to be added according to their approval) and subsequently, to give Gilead affiliates across the EMEA region engagement opportunities with registered haematology experts for their local / regional non-promotional speaking events.</gtr:impact><gtr:outcomeId>58c02a0c2cc9a2.15485060</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>https://www.gileadfaculty.com</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Based on the discovery of Activated PI3K Delta Syndrome (APDS) GSK has announced a clinical trial of their Pi3Kd inhibitor GSK2269557.
This is supported by and MRC-MICA award, but build on work we have done on PI3Kd, including discovery that APDS leads to hyperactive PI3Kd in T cells.</gtr:description><gtr:id>F62E5322-D2E8-4BD3-ACA0-3F5E29E1D55B</gtr:id><gtr:impact>Another trial has been announced by Novartis.</gtr:impact><gtr:outcomeId>56ddc5b12f55d5.89211360</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cinical trial of GSK</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02593539</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>905AA056-7521-421C-8702-243A0775C275</gtr:id><gtr:title>PI3Kd promotes CD4(+) T-cell interactions with antigen-presenting cells by increasing LFA-1 binding to ICAM-1.</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b49ad587a24e114757eb7a2383a580fb"><gtr:id>b49ad587a24e114757eb7a2383a580fb</gtr:id><gtr:otherNames>Gar?on F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>56a8b455dd1473.84903732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B397C1F-BF2E-4A02-ADF3-98FAE0D9438F</gtr:id><gtr:title>PI3Kd and primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/021a4cd2ceaff04ecd23ad056283b77c"><gtr:id>021a4cd2ceaff04ecd23ad056283b77c</gtr:id><gtr:otherNames>Lucas CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>58c01b10761e83.14901004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8839F536-5E22-4677-9B57-2ACA9160FDC3</gtr:id><gtr:title>Phosphoinositide 3-kinase d gene mutation predisposes to respiratory infection and airway damage.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5d405946584af030b04daeee4c67d"><gtr:id>28a5d405946584af030b04daeee4c67d</gtr:id><gtr:otherNames>Angulo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5447882a4b8d97.98440481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C56F316B-21B6-4512-AA2A-4D457CFF4976</gtr:id><gtr:title>Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b655a19e2deeae86c8bdddb8a40588e"><gtr:id>7b655a19e2deeae86c8bdddb8a40588e</gtr:id><gtr:otherNames>Okkenhaug K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn><gtr:outcomeId>58c01b109b7f49.57988775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A59C87E1-247C-48B4-A515-907FB692CD5E</gtr:id><gtr:title>A protocol for construction of gene targeting vectors and generation of homologous recombinant embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae27f0380bc38c5bbfcdf174186e5a7"><gtr:id>bae27f0380bc38c5bbfcdf174186e5a7</gtr:id><gtr:otherNames>Bouabe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5447882ac16438.18584020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20DFB081-3F89-4371-BB6B-43BFE6F66B3A</gtr:id><gtr:title>Signaling by the phosphoinositide 3-kinase family in immune cells.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b655a19e2deeae86c8bdddb8a40588e"><gtr:id>7b655a19e2deeae86c8bdddb8a40588e</gtr:id><gtr:otherNames>Okkenhaug K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>5447882b9654f5.95125748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>635F6E2A-F8FE-4A1C-B630-121004E7EF99</gtr:id><gtr:title>The transcription factor BACH2 promotes tumor immunosuppression.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cc5ada1f83b72c8e6fb9e8e76fdd03b"><gtr:id>2cc5ada1f83b72c8e6fb9e8e76fdd03b</gtr:id><gtr:otherNames>Roychoudhuri R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>56a8b455ad82d5.06140041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA8F02F-246F-45B8-832D-78D37F2B4925</gtr:id><gtr:title>Gene targeting in mice: a review.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae27f0380bc38c5bbfcdf174186e5a7"><gtr:id>bae27f0380bc38c5bbfcdf174186e5a7</gtr:id><gtr:otherNames>Bouabe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5447882b000867.43985817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C7CBED9-6A4B-49FE-9EA9-E05B5154A88C</gtr:id><gtr:title>PI3Kd Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc3bd176048b3e6684085d272855c357"><gtr:id>cc3bd176048b3e6684085d272855c357</gtr:id><gtr:otherNames>Pearce VQ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5675eacabb358</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/0000H329</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>